Fintel reports that on June 6, 2025, Goldman Sachs initiated coverage of Teva Pharmaceutical Industries Limited - Depositary ...

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection ...

Sound Shore Management, an investment management firm, has released its investor letter for the first quarter of 2025. A copy ...

In 2020, we committed to launching eight Access to Medicines programs by 2025, aimed at providing treatments to underserved ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced today that its investigational drug TEV-53408 has received Fast ...

Teva Pharmaceutical Industries (TEVA) announced the pricing and early acceptance results of its previously announced tender offers to buy for cash the outstanding notes.

Teva Pharmaceutical (TEVA) stock, Amneal Pharma (AMRX) stock receive Buy ratings and Viatris (VTRS) stock receives a Neutral rating at Goldman Sachs. Read more here.

Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's ...

Investing.com -- Goldman Sachs initiated coverage on U.S.-listed generic pharmaceutical companies with Buy ratings on Teva ...

Teva outlines acceleration path into a leading biopharma companyInnovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab), UZEDY® ...

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its previously announced ...